Discontinuation Cluster · SNRI
Cymbalta (Duloxetine) Onsite Taper
Onsite duloxetine (Cymbalta) taper bridged with iboga TA — capsule-bead micro-tapering under continuous telemetry.
Generic name
Duloxetine
Drug class
SNRI
Half-life class
intermediate
Plasma half-life
≈ 12 hours
Typical dose range
20–120 mg/day
Onsite taper duration
14–24 days onsite
TA bridge
Iboga TA 75–150 mg BID (sub-psychoactive)
Quick Answer
Can I taper off Cymbalta (Duloxetine) at MindScape?
Reviewed by Dr. Arellano, M.D. — May 2026
Withdrawal Profile
- Brain zaps and electric-shock sensations
- Dizziness and gait instability
- Noradrenergic rebound — sweating, BP elevation
- Anxiety crises, irritability
- Sleep disruption, vivid dreams
Why It's Hard To Taper At Home
- Capsule-bead formulation makes accurate micro-tapering at home almost impossible.
- Both serotonergic and noradrenergic components — same receptor breadth challenge as venlafaxine.
- Discontinuation syndrome frequently mistaken for chronic-pain relapse (duloxetine is also indicated for fibromyalgia and neuropathic pain).
MindScape Onsite Protocol
- Capsule-bead counting or compounded preparation for hyperbolic taper.
- Iboga TA bridge 75–150 mg BID covering both 5-HT and noradrenergic withdrawal.
- Continuous telemetry with BP and HR monitoring.
- Symptom-driven adjuncts: magnesium, hydroxyzine, ondansetron.
Day-By-Day Patient Experience
- Days 1–4: workup, magnesium loading, first reduction with TA cover.
- Days 5–14: hyperbolic bead-count step-downs; BP and noradrenergic monitoring.
- Days 15–20: full discontinuation; integration begins.
- Days 21–24: optional ibogaine HCl flood and post-flood tail.
Day-counts and step-cadences are illustrative ranges, not personal medical advice. Individual taper duration is determined onsite by the medical team after baseline workup.
Citations & Reading
- Horowitz MA, Taylor D. (2019). Lancet Psychiatry, 6(6), 538-546.
For the broader iboga-TA evidence base, see the 2026 evidence-base review and the onsite taper cohort methodology page.